Savara ($SVRA) Stock Hub: ERS Encore, November FDA Review and Conditional Funding

01 Executive Summary

Savara is a Nasdaq-listed biopharmaceutical company now headquartered in Yardley, Pennsylvania. Molgramostim inhalation solution, proposed trade name MOLBREEVI, is its sole development programme. It is an investigational recombinant human GM-CSF delivered using a PARI eFlow nebulizer for autoimmune pulmonary alveolar proteinosis (aPAP). The 70-employee count is a historical annual-report figure, not a verified September headcount.

Autoimmune PAP is a disease in which antibodies against GM-CSF disable the alveolar macrophages that clear surfactant from the lung. Surfactant accumulates, gas exchange deteriorates, and patients become progressively breathless. Roughly ninety per cent of all pulmonary alveolar proteinosis is the autoimmune form. Savara’s own filings put diagnosed prevalence at six to seven cases per million people in the United States, with similar or higher rates reported elsewhere. There is no approved medicine for the condition in the United States or in Europe. The standard intervention is whole lung lavage, a procedure in which a lung is washed out with saline under general anaesthesia, which the company describes in its filings as non-standardised.

The clinical case rests on IMPALA-2, a Phase 3 trial that randomised 164 patients, 81 to molgramostim and 83 to placebo, across 43 sites in 16 countries. The primary endpoint, the change from baseline at week 24 in percentage of predicted diffusing capacity of the lung for carbon monoxide adjusted for haemoglobin, was met: 9.8 percentage points against 3.8, a difference of 6.0 points with a 95% confidence interval of 2.5 to 9.4 and a p value below 0.001, published in the New England Journal of Medicine in August 2025. The separation widened at week 48 and the open-label extension data presented at the American Thoracic Society conference in May 2026 showed the treated arm at a mean 14.7-point improvement from baseline through week 96, with patients who crossed over from placebo gaining 8.8 points during weeks 48 to 96.

Savara completed the rolling BLA in March 2025 and received a refuse-to-file letter in May. The company described manufacturing comparability work and said the letter was not due to safety concerns or a request for additional efficacy studies. It resubmitted in December 2025 with Fujifilm as drug-substance supplier; FDA accepted it with Priority Review in February 2026. The April extension set November 22 as the target. Company expectations are MHRA Q4 2026 and EMA Q1 2027.

At June 30, cash, equivalents and short-term investments were $173.034 million, versus $235.702 million at year-end. Debt carrying value was about $30.1 million. Q2 net loss was $40.228 million, including $7.8 million of share-based compensation. G&A grew 78.2% as launch preparation expanded. Additional Hercules borrowing of up to $75 million and a $75 million RTW royalty purchase are conditional sources of future funding, subject to approval, contractual conditions and deadlines; neither is June cash.

02 The November 22 Date, And How The Company Got There

The sequence matters more than the date, because the sequence is what a reviewer will have in front of them.

December 2024 to March 2025: the rolling submission

Savara began a rolling submission of the Biologics License Application in December 2024 and completed it in March 2025, requesting Priority Review. A rolling submission allows a sponsor with a Fast Track designation to file sections of an application as they are completed rather than all at once.

May 2025: refuse to file

The FDA issued a refuse-to-file letter. On the company’s account in its annual report, the letter did not rest on safety concerns and the agency did not request or recommend additional efficacy studies; the existing designations were unaffected. A Type A meeting followed, at which the company reached alignment on demonstrating comparability between drug substance made by GEMA Biotech, which supplied the material used in the trials, and drug substance made by FUJIFILM Diosynth, which was being brought in as the commercial manufacturer. A refuse-to-file decision means the agency has judged the application incomplete enough not to begin substantive review, and it cost roughly seven months.

December 2025 to February 2026: resubmission and acceptance

The application was resubmitted in December 2025 with Fujifilm as the drug substance supplier. In February 2026 the FDA formally filed it and granted Priority Review, setting a target action date of August 22, 2026. Priority Review shortens the agency’s goal from ten months to six from the filing date, and is granted where a product would provide a significant improvement in the treatment of a serious condition.

March 6, 2026: the Day 74 Letter

On March 6, Savara reported that the Day 74 Letter indicated no advisory committee was planned. This describes the review schedule at that time. It does not establish that reviewers have no outstanding questions or that approval is more likely.

April 15, 2026: the three-month extension

On April 15, Savara announced that FDA classified its responses to information requests as a major amendment and extended the target from August 22 to November 22, 2026. The company said the correspondence did not cite safety, efficacy or manufacturing concerns. That is the sponsor’s account of the correspondence, not an FDA clearance of those review areas; retaining Priority Review does not predict the outcome.

03 What The Company Actually Is

Savara has one programme. The 10-Q states it plainly: molgramostim inhalation solution is “the Company’s sole program”. There is no second asset to fall back on, no partnered pipeline throwing off milestone payments, and no revenue of any kind. The corporate history includes divested and discontinued respiratory assets, and what remains is an inhaled biologic and the organisation built to sell it.

The company outsources what it can. Drug substance is manufactured by FUJIFILM Diosynth Biotechnologies in Billingham, United Kingdom, with GEMA Biotech in Buenos Aires retained as a potential second source. Drug product is made by Patheon UK, part of Thermo Fisher Scientific. The nebuliser is the PARI eFlow, licensed exclusively for pulmonary delivery of recombinant human GM-CSF in this indication. Clinical operations for IMPALA-2 and the paediatric IMPACT study run through Parexel. Roughly seventy people manage that network, which is a very small number for a company preparing a commercial launch on two continents.

The finance leadership changed in July 2026. Matt Pauls has been Chair and Chief Executive Officer since December 2020, having previously run Strongbridge Biopharma and held commercial roles at Insmed and Shire. Yazmine Wasfi became Chief Medical Officer in October 2025 and is a co-author on the IMPALA-2 publication. Robert Lutz, Chief Operating Officer since February 2023, added the finance role and became Chief Financial and Operating Officer on July 15, 2026, when David Lowrance resigned as Chief Financial and Administrative Officer for health reasons, as disclosed in the Form 8-K filed on June 8, 2026. Braden Parker has been Chief Commercial Officer since September 2024. The roles of Chair and Chief Executive are combined, with Joseph McCracken serving as Lead Independent Director.

The Langhorne lease ended June 30, 2026. A roughly 10,795-square-foot Yardley office lease began July 1 for 65 months, with annual rent around $0.3 million. Office size does not establish the number of diagnosed or commercially addressable patients.

04 Autoimmune PAP: The Disease, The Population, The Current Treatment

Pulmonary alveolar proteinosis is a syndrome in which surfactant, the lipoprotein material that keeps the alveoli open, accumulates in the air spaces and interferes with gas exchange. In the autoimmune form, which accounts for roughly ninety per cent of cases, the cause is an antibody directed against GM-CSF. Alveolar macrophages need GM-CSF signalling to catabolise surfactant; when the signal is neutralised, clearance fails. Patients present with progressive breathlessness on exertion, cough and fatigue, typically between thirty and fifty years of age, and the disease can advance to pulmonary fibrosis, respiratory failure and, in the worst cases, lung transplantation.

Molgramostim addresses that mechanism directly by delivering GM-CSF into the lung at a dose intended to overwhelm the local autoantibody, restoring macrophage function where the disease is. Delivery matters: systemic GM-CSF circulates everywhere and reaches the alveolar space poorly, which is one reason an inhaled formulation is the approach in development rather than an injection.

How many patients

Savara’s annual report gives an estimated diagnosed prevalence of six to seven cases per million people in the United States, and notes that similar or higher prevalence has been reported elsewhere, with one study estimating Japan at three to four times that rate. Applying six to seven per million to a United States population of roughly 340 million produces something on the order of two thousand to two thousand four hundred diagnosed patients of all types, of whom about ninety per cent would be the autoimmune form. That arithmetic is a Merlintrader derivation from the company’s prevalence figure, not a company estimate, and Savara does not publish a treatable-population number in its filings. Diagnosed prevalence is also not the same as identified and treated patients, and in rare disease the gap between the two is usually large.

The company has spent money on closing that gap. In December 2023 it launched aPAP ClearPath in the United States, a no-charge third-party testing programme for GM-CSF autoantibodies run through a CLIA-certified laboratory, and in September 2024 it started a European disease-awareness campaign. Diagnostic infrastructure built before approval is what determines whether a launch finds patients in year one or year four.

What patients get today

Nothing is approved for autoimmune PAP in the United States or Europe. Whole lung lavage remains the intervention of record: under general anaesthesia one lung is ventilated while the other is repeatedly filled with saline and drained, removing accumulated material. It is performed at specialised centres, it is not standardised across institutions, and it treats the accumulation rather than the cause, so it is repeated as the disease returns. Some United States patients use pharmacy-compounded sargramostim off label; Savara states it cannot assess either the effectiveness of that practice or how many patients follow it. In Japan, sargramostim was approved for autoimmune PAP in April 2024, which establishes a regulatory precedent for the GM-CSF mechanism in this disease in one major market.

05 IMPALA-2 Read Precisely, Including The Part That Did Not Work

IMPALA-2, registered as NCT04544293, randomised 164 adults with autoimmune PAP one to one, 81 to inhaled molgramostim 300 micrograms once daily and 83 to placebo, at 43 sites in 16 countries. Entry required a diffusing capacity at or below seventy per cent of predicted and confirmed anti-GM-CSF autoantibodies. The double-blind period ran 48 weeks and was followed by a 96-week open-label period in which every patient receives active drug. Whole lung lavage was permitted as rescue. The company describes it as the largest placebo-controlled trial ever conducted in the disease, which the enrolment figures support.

The primary DLCO endpoint and week-48 DLCO supported efficacy, with SGRQ total also positive at week 24. The secondary outcomes require multiplicity control: nominal p-values below 0.05 are not automatically confirmatory. The public statistical analysis plan provides the missing explanation rather than leaving an unexplained conflict between the paper and annual report.

The April 24, 2024 statistical plan, section 5.3.1 and Figure 2, first tests DLCO at weeks 24 and 48, then splits alpha between two secondary-endpoint families and applies Hochberg within each. Applying the published week-24 p-values gives exercise capacity 0.0845 versus 0.025, activity 0.0149 versus 0.0125, and total SGRQ about 0.007 versus 0.0083. Only the total score passes in that family. Week-48 activity p=0.1216, total p=0.1046 and exercise p=0.0234 likewise do not establish multiplicity-adjusted significance. Exercise capacity was measured as peak METs on a treadmill, not simply distance walked. This calculation explains nominal versus adjusted significance; it is not an FDA conclusion.

The May 19, 2026 update reports 160 of 164 participants completing the double-blind period and all 160 entering the extension, with nine discontinuations by that cutoff. Retention informs feasibility and tolerability; it does not independently prove efficacy.

What happened in the first trial, and why it matters

The earlier IMPALA trial randomized 138 patients across continuous, intermittent and placebo groups. Its original primary A–a oxygen-gradient analysis did not reach significance. The subsequent protocol explains that oxygen supplementation confounded measurements in four participants; post-hoc exclusion changed the result. The 2020 publication reported a continuous-treatment difference of −6.2 mmHg, p=0.03, and SGRQ-total difference of −7.4 points, p=0.01. These analyses should not be described as an original prespecified primary-endpoint success. IMPALA-2 used DLCO as its primary endpoint and omitted the intermittent arm; the separate IMPALA-X study was terminated in 2021.

Public statistical analysis plan, section 5.3 · Public protocol, prior IMPALA analysis

06 The Open-Label Extension And What It Adds

On May 19, 2026 Savara reported data from the first 48 weeks of the ongoing open-label period of IMPALA-2, presented at the American Thoracic Society International Conference in Orlando as poster board 403 by Bruce Trapnell. Because the open-label period follows the 48-week double-blind period, those data reach week 96 counting from baseline.

In the May 2026 open-label update, continuous-treatment patients gained a further mean 2.8 DLCO points during weeks 48–96, with a mean 14.7-point change from baseline to week 96. Placebo crossover patients gained 8.8 points during weeks 48–96. Continuous-group SGRQ total/activity changes over the open-label year were −3.8/−4.2, and from baseline −15.0/−18.3; crossover changes were −6.5/−7.9. These descriptive means and their populations differ from the least-squares estimates in the controlled analysis; they should not be spliced into one continuous controlled comparison.

Of the 164 patients randomised, 160 completed the double-blind period and all 160 entered the open-label period, of whom nine discontinued, a retention of about ninety-four per cent. The company reports no study discontinuations due to treatment-related adverse events. Exercise capacity was not assessed during the open-label period.

The Same Data Return At The European Respiratory Society Congress

The ERS Congress runs September 5–9 in Barcelona. Savara’s August 24 announcement describes the September 6 oral and two posters as encore presentations of ATS material. No new dataset is promised by that announcement. It does not establish that no other update can occur before the November FDA target.

The oral, abstract OA2381, is scheduled for Sunday September 6 from 3:45 to 5:00 pm CEST in Hall 3 of the Fira Gran Via, within session 3J on clinical and scientific advances in rare lung diseases. It is presented by Bruce C. Trapnell of the University of Cincinnati, the lead clinical investigator on IMPALA-2, and covers long-term efficacy and safety from the open-label period described above. The same morning, from 8:00 to 9:30 in Hall 1, session PS-37 carries poster PA885 on exercise capacity, presented by Cormac McCarthy of University College Dublin, and poster PA886 on biomarker levels, presented by Yoshikazu Inoue of the NHO Kinki Chuo Chest Medical Center. An industry evening mini-symposium on autoimmune pulmonary alveolar proteinosis follows the same day from 5:30 to 7:00 pm in Room 3M.

These sessions provide scientific discussion and physician education. The event announcement does not revise the FDA target or the company’s EU and U.K. expectations. Conference discussion must be distinguished from a formal regulatory decision or a new controlled trial result.

07 The Regulatory Map: Three Jurisdictions, Three Clocks

The designations accumulated over several years and each does something specific. Fast Track allows rolling submission and more frequent interaction with the review division. Breakthrough Therapy adds intensive guidance and organisational commitment from the agency. Orphan Drug designation, held in both the United States and the European Union, brings fee relief and, on approval, seven years of market exclusivity in the United States and ten in the European Union, which for a disease with no approved competitor is the commercial moat. In the United Kingdom the MHRA granted an Innovation Passport in June 2022 and Promising Innovative Medicine status in August 2022. Paediatric investigation plans were accepted by the EMA in March 2024 and the MHRA in October 2024, and a paediatric open-label study, IMPACT, registered as NCT06431776, began enrolling in October 2025.

In the August 11 update, management prioritized potential U.S. launch preparation. The MHRA Q4 2026 window overlaps the November 22 FDA date: it does not prove that the British decision comes first. The EMA Q1 2027 expectation is also company guidance, not a guaranteed agency deadline.

One structural feature of the application deserves attention. MOLBREEVI is a drug-device combination: a liquid biologic plus a specific nebuliser. It is regulated as a drug through the Center for Drug Evaluation and Research, with the device centre supporting the review of the nebuliser. That means the approval package contains device elements as well as biologic ones, and the 2025 refuse-to-file arose on the manufacturing side rather than the clinical one, which is a reminder of where the residual execution risk has historically sat for this programme.

Orphan exclusivity is conditional on qualifying approval and legal requirements, with exceptions; it is not blanket protection against every alternative. The FDA goal, MHRA window and EMA expectation are distinct processes.

08 Manufacturing, The Device, And What Each Partner Takes

Supply, device and clinical contracts combine development costs already being incurred with future milestone, purchase and royalty obligations. Not all of these costs wait for product approval or sit outside the income statement.

Drug substance

GEMA Biotech in Argentina supplied the material used in IMPALA and IMPALA-2 under a supply agreement signed in April 2019 and amended in December 2022 and December 2023. On first marketing approval Savara owes GEMA a royalty in the low single digits of net sales in each country for up to ten years, and is subject to a purchase requirement for a percentage of the product it sells, which lapses if GEMA’s price exceeds an alternative supplier, if there is a shortage, or if GEMA fails to fill an order. FUJIFILM Diosynth was brought in under a master services agreement signed in February 2024 to take over technology transfer and commercial supply; the total estimated accumulated fees payable under that agreement and its work orders are $57.1 million. Three process performance qualification batches have been validated and the application was filed with Fujifilm as the drug substance supplier, with GEMA available as a possible second source after approval.

Drug product and device

Drug product is manufactured by Patheon UK, a division of Thermo Fisher Scientific, with a second source planned after commercialisation. The nebuliser comes from PARI Pharma of Starnberg, Germany, under a worldwide exclusive licence for pulmonary delivery of any recombinant human GM-CSF liquid formulation in this indication. Savara owes PARI approximately $0.6 million of contingent milestones tied to development activities and regulatory approval of the nebuliser, plus a royalty of 3.5% of net sales, and is barred from developing a competing inhalation device. PARI already has five FDA-approved nebulisers on the same eFlow platform, which reduces the novelty of the device component in a review.

Clinical operations

Parexel has run IMPALA-2 since January 2021 under a master services agreement; service fees, pass-through expenses and investigator fees over the life of the trial are estimated at approximately $51.3 million. The paediatric IMPACT study runs under a separate work order worth up to approximately $5.4 million depending on enrolment and site management.

Intellectual property

The European Patent Office granted patent number 4 496 611 in November 2025, covering the drug-device combination of a liquid solution and a nebuliser, jointly held by Savara and PARI, with protection running through March 2043. On July 30, 2026 the company announced that the European and Australian patent offices had granted patents on the liquid formulation itself, providing protection in those territories through March 2041. Orphan exclusivity, seven years in the United States and ten in the European Union, runs from approval and is independent of the patent estate.

The $57.1 million Fujifilm figure is an estimated cumulative contract/work-order cost, not an additional June payable in full. Future services carry cancellation fees. Existing eFlow-platform approvals do not constitute approval of the MOLBREEVI combination. Patent terms are territory-specific and subject to legal validity and maintenance.

09 The Financial Position

Cash and equivalents were $41.800 million and short-term investments $131.234 million on June 30, totaling $173.034 million. Operating cash use in H1 was about $62.8 million versus $53.5 million a year earlier. There was no public equity financing in the half, but option exercises generated $0.239 million; tax-withholding share repurchases used $0.245 million, leaving a small net financing outflow.

R&D remained substantial at $21.951 million in Q2, up $1.200 million or 5.8%; clinical and manufacturing work did not stop. G&A was $18.986 million, up $8.331 million or 78.2%. The company attributes roughly $7.5 million of the increase to higher personnel costs, including stock compensation and headcount, plus $0.8 million of commercial activity. Those figures explain the increase, not total personnel spending. H1 R&D/G&A were $45.349/$34.554 million and net loss $77.512 million.

The accumulated deficit reached $685.6 million at June 30, 2026. Total stockholders’ equity was $143.7 million and total assets $192.1 million, so the balance sheet is essentially the cash pile plus in-process research and development carried from earlier acquisitions.

Runway, stated carefully

A simple June 30 cash-to-H1-burn calculation gives about 16.5 months at an unchanged rate: 173.034 / (62.8 / 6). This is historical arithmetic, not September runway or company guidance. The filing says capital can fund many planned activities and further capital may be needed. Launch spending, timing of approval and financing conditions can materially change the result.

10 Capital Structure, Dilution And The Two Facilities

June 30 common shares were 205,399,365, plus 48,600,212 pre-funded warrant shares at a $0.001 exercise price. Together they represent approximately 254.000 million economic units, before other awards. The 10-Q also reports 160,000 vested deferred-settlement RSUs. The Q2 weighted-average EPS denominator of 253,569,891 is a period average, not the June ending count. On August 11 common shares were 205,460,015.

Outstanding awards included 12,227,121 options, 6,973,000 unvested RSUs and 4,562,000 PSUs. PSU payout ranges from zero to target and depends on specified regulatory/revenue milestones and continued service; FDA approval does not vest every award automatically. Legacy warrants cover 77,793 shares at $2.87. The August 11 S-8 registers an additional 18.9 million plan shares: registration is neither a cash offering nor evidence that all shares have been issued. Do not add plan capacity again to awards already counted.

The debt

The Hercules Capital loan agreement of March 2025 provided an initial $30 million tranche, drawn in March 2025 and used to repay a Silicon Valley Bank facility. A first amendment on January 26, 2026 restructured the facility to a maximum of $105 million and made $75 million of additional term loans conditional on the approval milestone, split into a first tranche of up to $45 million and a second of up to $30 million, each available through the earlier of 120 days after approval or June 30, 2027. Interest runs at the Wall Street Journal prime rate with a 6.0% floor plus 1.45%, which was 8.2% at June 30, 2026. Future minimum payments begin in 2028: $11.4 million that year, $14.7 million in 2029 and $6.0 million in 2030. The lenders hold a first-priority security interest in the company’s intellectual property, which converts to a negative pledge under defined conditions. The amendment also pushed back two financial covenants, the cash requirement to April 1, 2027 and a conditional minimum revenue covenant to September 30, 2027, if market capitalisation falls below stated thresholds.

The royalty sale

On October 29, 2025 Savara agreed with funds managed by RTW Investments to receive $75.0 million on FDA approval of MOLBREEVI on or before March 31, 2027, in exchange for a true sale of the right to a tiered royalty on United States net sales. The royalty runs from 7.0% down to 1.0% by annual sales band, with the 7.0% tier rising to 9.5% for a year if the prior year’s net sales miss a specified level, and payments end when RTW has received $187.5 million. A buy-back option allows the company to terminate on a change of control within two years of receiving the money, and a $4.0 million payment may be owed to RTW on a change of control occurring before approval. Savara is generally required to use part of the proceeds to repay debt, but an intercreditor agreement lets the Hercules borrowing stay outstanding.

The June balance plus the maximum $150 million of conditional funding would arithmetically total $323 million before subsequent cash burn, fees and other obligations. That is not a projected year-end cash balance. Hercules adds interest-bearing debt and RTW sells part of future U.S. revenue. Failure to obtain qualifying approval by the contractual deadlines could remove access; an earlier complete response letter is not itself proof that every financing path is permanently closed.

Hercules draw availability is subject to the agreement, approval milestone and timing, including the second tranche opening after full draw or expiry of the first. RTW also requires qualifying FDA approval by March 31, 2027 and satisfaction of closing terms. Neither agreement promises simultaneous same-day receipt of the full maximum.

S-8 · 2026-08-11 →

Ownership and control

The April 24 proxy, evaluated April 6 or earlier filing dates, lists NEA 24.471 million beneficial shares (11.94%), Bain 21.184 million (9.99%), Venrock 21.219 million (9.99%), Farallon 15.000 million (6.82%), Deerfield 13.569 million (6.62%), TCG Crossover 12.362 million (6.03%) and BlackRock 10.957 million (5.35%). These are historical beneficial holdings, not September trading positions.

Bain’s footnote identifies 14.051 million common shares plus warrants over 26.457 million, subject to a 9.99% exercise blocker. A blocked beneficial-ownership table is therefore not the same as total economic exposure. The group of directors and officers was reported at 10.854 million beneficial shares, 5.30%, under its own denominator and option rules. No sole majority holder is established by this table.

SEC proxy · 2026-04-24 →

11 The Commercial Build-Out, And What The Filings Do Not Say

The clearest evidence that Savara is preparing to sell something is in the general and administrative line. It rose 78.2% year on year in the second quarter, and the company attributes the increase to share-based compensation and to headcount growth “as we build out our commercial team ahead of and in support of our planned product launch”, adding that these investments reflect a strategy to establish the commercial infrastructure necessary to support an effective and timely launch. Braden Parker has been Chief Commercial Officer since September 2024, which places the start of that build roughly two years before the current target action date.

The reviewed filings and August results do not establish an approved commercial price, first-year patient target or revenue guidance. A revenue model therefore needs explicit assumptions about diagnosis, referral, eligibility, reimbursement, treatment uptake and net pricing. Absence of those verified figures should not be expanded into a claim that management has no launch or payer strategy.

aPAP ClearPath provides diagnostic testing support. Pediatric IMPACT (NCT06431776) is recruiting, with actual start October 22, 2025; the record last updated February 19, 2026 estimates primary completion in June 2027 and study completion in December 2027. These are registry estimates, not promised readout dates or a pediatric approval.

Potential sales economics include low-single-digit GEMA royalties, a 3.5% PARI royalty and, if the RTW transaction closes, tiered U.S. royalties initially reaching 7%, or 9.5% in the specified underperformance case, until the $187.5 million cap. These reduce retained economics; their eventual accounting presentation must not be assumed to be identical.

12 Market Data And The Short Position

Marketstack’s September 4 regular-session close was $5.37, unchanged from September 3, with 624,706 shares traded. August 11 common shares imply approximately $1.103 billion of basic equity value. Applying $5.37 to June common shares plus pre-funded warrants gives approximately $1.364 billion before other awards; the dates and definitions differ.

Finviz retrieved September 5 reports float 102.79 million, short float 37.46%, short ratio 21.71 and average daily volume 1.774 million. These fields can have different underlying reporting dates; days-to-cover is a ratio, not a deadline or forecast. Finviz volume of 625,457 differs slightly from Marketstack. Short interest can affect liquidity and volatility without guaranteeing direction or a squeeze.

Finviz insider ownership 49.97% and institutional ownership 66.98% are overlapping provider classifications, not pieces of a 100% ownership pie. A date-consistent cap table must account for beneficial ownership rules and pre-funded warrants separately. Current analyst targets were not verified against original research and are not used as valuation evidence.

Finviz →

13 Retail Sentiment

StockTwits, September 5: normalized sentiment 37/100 — BEARISH; message activity 47/100 — NORMAL; 22,729 watchers. These are normalized scores, not the percentage of investors on either side. The connector’s $5.39 quote is timestamped September 4 at 19:30 Eastern and differs from the regular-session close used above.

The low-traffic stream contains 13 messages in the last 15 days, with takeover speculation, FDA timing and ERS discussion. Missing conference appearances do not prove a sale process or early approval. Several posts blur company statements and agency findings. Social content is evidence of discussion, not clinical or regulatory verification.

StockTwits →

14 The Case Made By Those Who Are Positive

What follows is the argument as its holders make it, not a Merlintrader view.

A positive pivotal primary endpoint, published controlled results and supportive longer-exposure observations provide the clinical foundation. Peer review does not itself determine whether the full BLA meets FDA requirements.

Priority Review, Fast Track, Breakthrough Therapy and orphan designations support development and review processes. Parallel applications diversify the regulatory timetable, while the U.K. Q4 window overlaps the U.S. November target. None guarantees approval.

The April extension allows more review time for a major amendment. Savara’s account of the correspondence did not cite new concerns in the three areas named. That statement and continued Priority Review cannot establish that substantive review issues have been resolved.

Savara’s annual report says it was not aware of competing inhaled GM-CSF development programmes for aPAP. This is a dated company assessment, not proof that competition cannot emerge. Whole-lung lavage and off-label treatment remain alternatives; patents and possible orphan exclusivity have territory, indication and legal limits.

June liquidity and conditional financing agreements provide a funding framework. The half-year had no public equity raise, but option exercises and equity compensation occurred. Non-dilutive funding still carries borrowing or royalty costs and requires satisfaction of the contracts.

The mechanism has a regulatory precedent. Sargramostim was approved for autoimmune PAP in Japan in April 2024, so a regulator has already accepted GM-CSF replacement as a treatment for this disease, albeit in a different formulation and jurisdiction.

The durability data keep pointing the same way. Ninety-eight per cent of randomised patients completed the blinded period, all completers entered the extension, retention through the open-label year was ninety-four per cent, and the crossover group improved 8.8 points of diffusing capacity after switching from placebo to drug.

15 The Case Made By Those Who Are Sceptical, And The Red Flags

Single-program concentration exposes the company to a regulatory delay, restrictive label or complete response letter. Such an outcome could require additional work and capital. It would not establish that all jurisdictions or every future commercial path had permanently failed.

The 2025 refuse-to-file and transfer of manufacturing highlight the importance of CMC and comparability. The reviewed public disclosures do not prove that the April 2026 information requests concerned a particular unresolved manufacturing defect. Clinical, device, labeling and manufacturing review remain part of the full assessment.

The activity and exercise findings are limited by multiplicity, as explained using the public statistical plan. Numerical improvement and a nominal p-value are supportive observations, not interchangeable with a prespecified confirmatory result.

The annual report’s six-to-seven-per-million estimate describes diagnosed PAP, with about 90% autoimmune. It is not a verified list of accessible patients, nor a forecast of treated patients or revenue. Referral, eligibility, payer access and net price remain material modeling uncertainties.

Potential sales economics include low-single-digit GEMA royalties, a 3.5% PARI royalty and, if the RTW transaction closes, tiered U.S. royalties initially reaching 7%, or 9.5% in the specified underperformance case, until the $187.5 million cap. These reduce retained economics; their eventual accounting presentation must not be assumed to be identical.

G&A rose ahead of potential approval, increasing the cash exposure if launch is delayed. Management could adjust spending, but the speed and cost of any changes are not verified. Historical burn cannot specify the cost or duration of a future review cycle.

June common shares plus pre-funded warrants form an economic base approximately 23.7% larger than common shares alone, before other awards. Comparing valuation on different denominators can mislead; pre-funded warrants are not future financing proceeds of comparable size.

Robert Lutz assumed the combined finance and operations role on July 15 after David Lowrance’s disclosed health-related departure. This is an execution and workload consideration, not evidence of an accounting problem or an adverse regulatory signal.

16 Scenario Framework

The two paths below describe what would have to happen. They are not forecasts, they carry no probabilities and no price levels.

The decision concerns the full benefit-risk and quality package, not manufacturing alone. Checkpoints are September 6 ERS encore sessions; November 22 FDA target; company expectations for MHRA in Q4 2026 and EMA in Q1 2027; and contractual financing deadlines, including March 31, 2027 for qualifying RTW approval.

17 Bottom Line

Savara combines positive pivotal evidence and an accepted application with concentrated regulatory and launch risk. ERS is a dissemination event for previously presented findings. The next substantive tests are regulatory action, funding execution and ultimately patient access and net sales; none can be inferred from the absence of an advisory committee or takeover speculation.

What is verified. PDUFA target action date November 22, 2026, after a three-month extension announced April 15, 2026. Priority Review granted February 2026; Day 74 Letter of March 6, 2026 indicating no advisory committee is planned. EMA validation March 2026 with a decision expected in the first quarter of 2027; MHRA validation April 2026 under a 150-day accelerated assessment with a decision expected in the fourth quarter of 2026. IMPALA-2: 164 patients randomised 81 to 83, week 24 DLCO +9.8 against +3.8 percentage points, difference 6.0 points, 95% CI 2.5 to 9.4, p<0.001; week 48 +11.6 against +4.7; SGRQ total −11.5 against −4.9 at week 24, p=0.007; no significant difference in the activity domain, which did not pass multiplicity adjustment. Open-label extension through week 96: +14.7 points from baseline on continuous treatment, +8.8 points during weeks 48 to 96 for patients crossing over from placebo. Cash and short-term investments $173.0 million at June 30, 2026, from $235.7 million at December 31, 2025; debt $30.1 million; six-month operating burn $62.8 million; accumulated deficit $685.6 million. Second-quarter net loss $40.2 million, $(0.16) per share, with research and development at $22.0 million and general and administrative at $19.0 million. 205,399,365 common shares outstanding plus 48,600,212 shares under pre-funded warrants at $0.001. Hercules facility up to $105 million with $75 million conditional on approval; RTW payment of $75.0 million on approval by March 31, 2027 against a tiered 7.0% to 1.0% United States royalty capped at $187.5 million.

Unresolved questions include the FDA outcome and label, remaining regulatory requests, actual drawdown and royalty-closing timing, launch pricing, reimbursed patient access and future burn. The statistical multiplicity explanation is now documented in the public plan; it is no longer listed as unknowable.

The dates that settle the question: the fourth quarter of 2026, for the MHRA decision in the United Kingdom; November 22, 2026, the FDA target action date on which the entire equity turns; the first quarter of 2027, for the European decision; and March 31, 2027, the outside date after which the RTW royalty payment is no longer available on approval.